Janux Therapeutics (NASDAQ:JANX) Earns Buy Rating from Analysts at UBS Group

UBS Group began coverage on shares of Janux Therapeutics (NASDAQ:JANX) in a research report sent to investors on Thursday, MarketBeat.com reports. The firm issued a buy rating and a $69.00 price target on the stock.

Other analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a report on Monday, August 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a research note on Monday, September 16th. Wedbush reissued an “outperform” rating and issued a $74.00 target price on shares of Janux Therapeutics in a research note on Thursday, August 8th. Scotiabank decreased their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. Finally, Stifel Nicolaus assumed coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $70.00 price target on the stock. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Janux Therapeutics has an average rating of “Moderate Buy” and an average price target of $66.44.

Janux Therapeutics Stock Up 0.2 %

Shares of JANX stock opened at $53.41 on Thursday. The firm has a market cap of $2.79 billion, a price-to-earnings ratio of -58.69 and a beta of 3.54. Janux Therapeutics has a 12 month low of $5.65 and a 12 month high of $65.60. The stock has a 50-day moving average price of $47.10 and a 200 day moving average price of $45.99.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.20. The company had revenue of $8.90 million for the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The company’s revenue for the quarter was up 709.1% compared to the same quarter last year. Sell-side analysts predict that Janux Therapeutics will post -1.18 earnings per share for the current fiscal year.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the sale, the chief executive officer now directly owns 307,054 shares in the company, valued at approximately $14,219,670.74. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, insider Andrew Hollman Meyer sold 50,000 shares of the business’s stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the sale, the insider now directly owns 67,592 shares in the company, valued at $3,106,528.32. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of the stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $46.31, for a total value of $1,157,750.00. Following the transaction, the chief executive officer now owns 307,054 shares of the company’s stock, valued at approximately $14,219,670.74. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 395,610 shares of company stock worth $17,950,166. 29.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its stake in shares of Janux Therapeutics by 64.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,033 shares of the company’s stock worth $456,000 after acquiring an additional 3,943 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in Janux Therapeutics by 639.5% during the third quarter. Nisa Investment Advisors LLC now owns 20,343 shares of the company’s stock worth $924,000 after purchasing an additional 17,592 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Janux Therapeutics in the 2nd quarter valued at $5,715,000. Finally, Blue Owl Capital Holdings LP acquired a new stake in Janux Therapeutics in the 2nd quarter valued at $1,676,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.